FI85596B - Foerfarande foer framstaellning av en aerosolspray som innehaoller liposomer, daervid anvaend foerpackning och anvaendning av en komposition i foerpackningen. - Google Patents
Foerfarande foer framstaellning av en aerosolspray som innehaoller liposomer, daervid anvaend foerpackning och anvaendning av en komposition i foerpackningen. Download PDFInfo
- Publication number
- FI85596B FI85596B FI860518A FI860518A FI85596B FI 85596 B FI85596 B FI 85596B FI 860518 A FI860518 A FI 860518A FI 860518 A FI860518 A FI 860518A FI 85596 B FI85596 B FI 85596B
- Authority
- FI
- Finland
- Prior art keywords
- lipid
- component
- solution
- propellant
- chamber
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 claims abstract description 70
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 239000003380 propellant Substances 0.000 claims abstract description 43
- 239000000463 material Substances 0.000 claims abstract description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 239000002502 liposome Substances 0.000 claims abstract description 35
- 239000000443 aerosol Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000007921 spray Substances 0.000 claims abstract description 22
- 239000003960 organic solvent Substances 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 239000011872 intimate mixture Substances 0.000 claims abstract 2
- 239000013543 active substance Substances 0.000 claims description 44
- 239000000126 substance Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 239000007789 gas Substances 0.000 claims description 10
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- -1 compounds dicetylphosphate Chemical class 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 6
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 239000012042 active reagent Substances 0.000 claims description 2
- 239000004009 herbicide Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 239000000575 pesticide Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000003892 spreading Methods 0.000 claims 4
- 241000196324 Embryophyta Species 0.000 claims 2
- 241001122767 Theaceae Species 0.000 claims 1
- 229940093541 dicetylphosphate Drugs 0.000 claims 1
- 239000002737 fuel gas Substances 0.000 claims 1
- 230000002363 herbicidal effect Effects 0.000 claims 1
- 230000008635 plant growth Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 239000011149 active material Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 27
- 239000000787 lecithin Substances 0.000 description 18
- 229940067606 lecithin Drugs 0.000 description 18
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 17
- 235000010445 lecithin Nutrition 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 9
- 238000005507 spraying Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 5
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 5
- 235000018660 ammonium molybdate Nutrition 0.000 description 5
- 239000011609 ammonium molybdate Substances 0.000 description 5
- 229940010552 ammonium molybdate Drugs 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 5
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000001088 anti-asthma Effects 0.000 description 3
- 239000000924 antiasthmatic agent Substances 0.000 description 3
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 3
- 229960000585 bitolterol mesylate Drugs 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 2
- XLLNINGEDIOQGQ-UHFFFAOYSA-N [acetyloxy(hydroxy)phosphoryl] acetate Chemical compound CC(=O)OP(O)(=O)OC(C)=O XLLNINGEDIOQGQ-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960000912 stanozolol Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 241001580017 Jana Species 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Cosmetics (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Steroid Compounds (AREA)
Claims (17)
1. Förfarande för framställning av liposomer ur en blandning, som innehäller en lipidkomponent och vatten, 5 varvid man gör en lösning av lipidkomponenten i ett orga-niskt lösningsmedel, förenar den sälunda erhällna lösnin-gen med en annan komponent, som innehäller vatten och bildar en blandning av kombinationen, känne-t e c k n a t därav, att man för en del av kombinationen 10 som sagda blandning under tryck genom ett munstycke, för att fä en intim blandning därav och sälunda producera en aerosolspray, som innehäller liposomer.
2. Förfarande enligt patentkravet 1, känne-t e c k n a t därav, att i kombinationen ingär ett ak- 15 tivt ämne, som är biologiskt aktivt och/eller använbart vid behandling eller skötsel av mänsko- eller djurkroppen eller växter.
3. Förfarande enligt patentkravet 2, känne-t e c k n a t därav, att det aktiva ämnet är löst i det 20 organiska lösningsmedlet.
4. Förfarande enligt patentkravet 2 eller 3, kännetecknat därav, att det aktiva ämnet är: (i) terapeutiskt eller kosmetiskt aktivt; (ii) ett biologiskt aktivt reagens . . 25 (iii) en eller flere föreningar med näringsvärde; eller (iv) en pesticid, herbicid, eller ett ämne som reglerar växternas tillväxt.
5. Förfarande enligt nägot av de föregäende pa- 30 tentkraven, kännetecknat därav, att lipidkomponenten innehäller ett fosfolipidmaterial och har valts sä, att man fär en positivt laddad, en negativt laddad eller en neutral liposom, och företrädesvis är fosfolipiden fosfatidylkolin, fosfatidyletanolamin eller 35 fosfatidylserin, och företrädesvis innehäller lipidkom- 27 8 5 596 ponenten ett eller flere av dessa ämnen som sädant eller ett eller flere av dessa ämnen tillsammans med kolesterol och/eller en av föreningarna dicetylfosfat, fosfatidinsy-ra eller stearylamln. 5
6. Förfarande enligt nägot av de föregäende pa- tentkraven, kännetecknat därav, att den vat-tenhaltiga komponenten innehäller buffertmaterial.
7. Förfarande enligt nägot av de föregäende pa-tentkraven kännetecknat därav, att spray- 10 trycket ästadkoms med ätminstone en aerosoldrivgas.
8. Förfarande enligt nägot av patentkraven 2-7, kännetecknat därav, att blandningen sprayas pä ett sätt som ger en uppmätt dos av ifrägavarande akti-va ämne.
9. En förpackning att användas vid framställningen av en liposomal aerosol innehällande en eller flere kam-mare och ett spridningsarrangemang, känneteck-n a d därav, att ätminstone en första kammare innehäller en lipidkomponent i ett organiskt lösningsmedel och en 20 vattenhaltig komponent, varvid den första kammaren och/-eller den andra kammaren innehäller ätminstone en driv-gas, och spridningsarrangemanget är sädant med vars hjälp man genom munstycket kan dispergera en blandning, som innehäller lipidlösningen och den vattenhaltiga kom- 25 ponenten, som spray under tryck, vilket erhällits med drivgas eller -gaser.
10. Förpackning enligt patentkravet 9, k ä n -netecknad därav, att den första kammaren innehäller aktivt ämne, som är användbart vid behandling av 30 mänsko- eller djurkroppen, med som inte är ett terapeu- tiskt användbart ämne eller som är användbart vid behandling eller skötsel av växter.
11. Förpackning enligt patentkravet 10, k ä n -netecknad därav, att spridningsarrangemanget är 35 sädant att en uppmätt dos av ifrägavarande ämne kan tas 28 85596 frän förpackningen.
12. Förpackning enligt nägot av patentkraven 9 -11, kännetecknad därav, att lipidlösningen, den vattenhaltiga komponenten, drivgasen (-gaserna) och 5 det aktiva ämnet är sädana som definierats i nägot av patentkraven 3-7 förutom att det aktiva ämnet inte är te-rapeutiskt aktivt.
13. Förpackning enligt nägot av patentkraven 9 -12 att användas vid framställningen av en liposomal aero- 10 soi, kännetecknad därav, att förpackningen innehäller ätminstone en första kammare innehällande en lösning av lipidkomponenten i ett organiskt lösningsmed-el, ett system för att mata in den vattenhaltiga komponenten i kammaren, varvid den första kammaren, den andra 15 kammaren och/eller den vattenhaltiga komponenten innehäl-ler ätminstone en drivgas, och förpackningen innehäller ett spridningsarrangemang med vars hjälp man genom mun-stycket kan dispergera blandningen som innehäller ifräga-varande lösning och den vattenhaltiga komponenten, som 20 spray under tryck, vilket erhällits med drivgas eller -gaser.
14. Användningen av en komposition, som innehäller en vattenhaltig komponent och en lösning av en lipidkom-ponent i ett organiskt lösningsmedel och eventuellt driv- 25 gas eller -gaser och/eller aktivt ämne eller ämnen, som definierats i patentkravet 2, förutom terapeutiskt an-vändbart ämne, i en förpackning enligt nägot av patentkraven 9-13, för att erhälla flere enhetsdoser, vilka innehäller liposomalt material.
15. Användning enligt patentkravet 14, kän netecknad därav, att kompositionen innehäller ca 45 - 70 vikt-% vatten, ca 2 - 10 vikt-% lipid, ca 4 - 20 - vikt-% organiskt lösningsmedel, och eventuellt ca 20 - 45 vikt-% drivgas. 29 85596
16. Användning enligt patentkravet 14 eller 15, kännetecknad därav, att ingrediensernas vikt-förhällanden i kompositionen är följande: Vatten : lipid- - ca 5:1 - ca 30:1; Lösningsmedel : lipid - ca 40:1 el-5 ler lägre t.ex. 1,86:1; Vatten : lösning - ätminstone ca 4:1; vatten : drivgas - ca 1,1:1 - ca 20:1; och /eller Drivgas : lösningsmedel - ca 1,3:1 - ca 12:1.
17. Användning enligt nägot av patentkraven 14 -16, kännetecknad därav, att lipidlösningen, 10 den vattenhaltiga komponenten, drivgasen (-gaserna) och det aktiva ämnet i kompositionen är sädana som definierts i patentkraven 3-7, förutom terapeutiskt användbart äm-ne.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB858502892A GB8502892D0 (en) | 1985-02-05 | 1985-02-05 | Aerosol composition |
| GB8502892 | 1985-02-05 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI860518A0 FI860518A0 (fi) | 1986-02-05 |
| FI860518A7 FI860518A7 (fi) | 1986-08-06 |
| FI85596B true FI85596B (fi) | 1992-01-31 |
| FI85596C FI85596C (sv) | 1992-05-11 |
Family
ID=10573974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI860518A FI85596C (sv) | 1985-02-05 | 1986-02-05 | Förfarande för framställning av en aerosolspray som innehåller liposom er, därvid använd förpackning och användning av en komposition i förpa ckningen |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0190926B1 (sv) |
| JP (1) | JPS61200849A (sv) |
| KR (1) | KR860006264A (sv) |
| AT (1) | ATE62411T1 (sv) |
| AU (1) | AU5284186A (sv) |
| DE (1) | DE3678587D1 (sv) |
| DK (1) | DK52686A (sv) |
| ES (1) | ES8900197A1 (sv) |
| FI (1) | FI85596C (sv) |
| GB (2) | GB8502892D0 (sv) |
| GR (1) | GR860350B (sv) |
| IE (1) | IE860313L (sv) |
| NO (1) | NO860402L (sv) |
| NZ (1) | NZ214895A (sv) |
| PT (1) | PT81966B (sv) |
| ZA (1) | ZA86658B (sv) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8603061D0 (en) * | 1986-02-07 | 1986-03-12 | Wellcome Found | Pesticidal formulations |
| AU598002B2 (en) * | 1986-07-15 | 1990-06-14 | Cilag Ltd. | Method of preparing single bilayered liposomes |
| IE63869B1 (en) * | 1986-11-06 | 1995-06-14 | Res Dev Foundation | Aerosols containing liposomes and method for their preparation |
| US5049391A (en) * | 1987-02-27 | 1991-09-17 | Terumo Kabushiki Kaisha | Liposome encapsulated hemoglobin |
| US5811119A (en) * | 1987-05-19 | 1998-09-22 | Board Of Regents, The University Of Texas | Formulation and use of carotenoids in treatment of cancer |
| EP0397774A1 (en) * | 1988-02-04 | 1990-11-22 | Board Of Regents, The University Of Texas System | Formulation and use of retinoids in treatment of cancer and other diseases |
| LU87449A1 (fr) * | 1989-02-09 | 1990-09-19 | Oreal | Procede de fabrication de mousses utilisables dans les domaines cosmetique et pharmaceutique et mousses obtenues par ce procede |
| US5554382A (en) * | 1993-05-28 | 1996-09-10 | Aphios Corporation | Methods and apparatus for making liposomes |
| EP0706374B1 (en) * | 1993-06-30 | 1997-12-10 | Genentech, Inc. | Method for preparing liposomes |
| AU7454698A (en) * | 1997-06-06 | 1998-12-21 | Shionogi & Co., Ltd. | Improvement in medicament administration system |
| FR2764798B1 (fr) * | 1997-06-23 | 2000-03-31 | Kisby Lab | Lotion capillaire, notamment destinee a favoriser l'elimination des pellicules et a redonner vigueur aux cheveux |
| KR100575070B1 (ko) * | 1997-09-29 | 2006-05-03 | 넥타르 테라퓨틱스 | 안정화된 생활성 제제 및 이의 사용 방법 |
| JP2000238936A (ja) | 1999-02-18 | 2000-09-05 | Riso Kagaku Corp | 孔版原紙ロールの芯管及びホルダ |
| US8814861B2 (en) | 2005-05-12 | 2014-08-26 | Innovatech, Llc | Electrosurgical electrode and method of manufacturing same |
| US7147634B2 (en) | 2005-05-12 | 2006-12-12 | Orion Industries, Ltd. | Electrosurgical electrode and method of manufacturing same |
| JPWO2007117024A1 (ja) * | 2006-04-11 | 2009-08-20 | 株式会社ウイングターフ | ガス処理方法 |
| JP4926215B2 (ja) * | 2009-07-31 | 2012-05-09 | 本田技研工業株式会社 | 能動型振動騒音制御装置 |
| KR102058256B1 (ko) * | 2011-06-17 | 2020-01-22 | 버그 엘엘씨 | 흡입성 약제학적 조성물들 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB780885A (en) * | 1955-05-03 | 1957-08-07 | Innoxa England Ltd | Foundation cream |
| GB993702A (en) * | 1961-11-10 | 1965-06-02 | Takeda Chemical Industries Ltd | An aerosol dispersing agent |
| GB1113886A (en) * | 1965-09-23 | 1968-05-15 | Chase Products Co | Antiperspirant composition |
| GB1281696A (en) * | 1968-12-27 | 1972-07-12 | Douglas Johnson | Improvements relating to photography and cinematography |
| NL7012832A (sv) * | 1970-08-29 | 1972-03-02 | ||
| GB1352062A (en) * | 1971-01-07 | 1974-05-15 | Johnson D | Method of processing exposed light-sensitive silver halide material |
| DE2115926C3 (de) * | 1971-04-01 | 1978-05-03 | C.H. Boehringer Sohn, 6507 Ingelheim | 1 -(4-Hydroxy-3-dimethylaminosuIfamidophenyI)-2-aminoäthanderivate, Verfahren zu ihrer Herstellung und diese enthaltende Mittel |
| ZA738303B (en) * | 1972-11-13 | 1975-06-25 | Colgate Palmolive Co | Shaving composition |
| GB1463964A (en) * | 1975-03-21 | 1977-02-09 | Follmer D W | Cookware lubricants |
| GB2001334B (en) * | 1977-07-19 | 1982-03-03 | Fisons Ltd | Pressurised aerosol formulation |
| GB8322178D0 (en) * | 1983-08-17 | 1983-09-21 | Sterwin Ag | Preparing aerosol compositions |
| EP0158441B2 (en) * | 1984-03-08 | 2001-04-04 | Phares Pharmaceutical Research N.V. | Liposome-forming composition |
-
1985
- 1985-02-05 GB GB858502892A patent/GB8502892D0/en active Pending
-
1986
- 1986-01-22 NZ NZ214895A patent/NZ214895A/xx unknown
- 1986-01-29 ZA ZA86658A patent/ZA86658B/xx unknown
- 1986-01-30 AU AU52841/86A patent/AU5284186A/en not_active Abandoned
- 1986-02-04 KR KR1019860000747A patent/KR860006264A/ko not_active Withdrawn
- 1986-02-04 IE IE860313A patent/IE860313L/xx unknown
- 1986-02-04 PT PT81966A patent/PT81966B/pt not_active IP Right Cessation
- 1986-02-04 DK DK52686A patent/DK52686A/da not_active Application Discontinuation
- 1986-02-05 GR GR860350A patent/GR860350B/el unknown
- 1986-02-05 ES ES551674A patent/ES8900197A1/es not_active Expired
- 1986-02-05 NO NO860402A patent/NO860402L/no unknown
- 1986-02-05 JP JP61023649A patent/JPS61200849A/ja active Pending
- 1986-02-05 FI FI860518A patent/FI85596C/sv not_active IP Right Cessation
- 1986-02-05 EP EP86300775A patent/EP0190926B1/en not_active Expired - Lifetime
- 1986-02-05 AT AT86300775T patent/ATE62411T1/de not_active IP Right Cessation
- 1986-02-05 DE DE8686300775T patent/DE3678587D1/de not_active Expired - Fee Related
- 1986-02-05 GB GB8602827A patent/GB2170815B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB2170815A (en) | 1986-08-13 |
| EP0190926A3 (en) | 1987-09-02 |
| DE3678587D1 (de) | 1991-05-16 |
| FI860518A0 (fi) | 1986-02-05 |
| AU5284186A (en) | 1986-08-14 |
| ZA86658B (en) | 1986-09-24 |
| PT81966A (en) | 1986-03-01 |
| NO860402L (no) | 1986-08-06 |
| GB2170815B (en) | 1989-07-05 |
| GB8502892D0 (en) | 1985-03-06 |
| EP0190926B1 (en) | 1991-04-10 |
| EP0190926A2 (en) | 1986-08-13 |
| KR860006264A (ko) | 1986-09-09 |
| IE860313L (en) | 1986-08-05 |
| ATE62411T1 (de) | 1991-04-15 |
| NZ214895A (en) | 1988-09-29 |
| ES8900197A1 (es) | 1989-03-16 |
| PT81966B (pt) | 1988-01-22 |
| FI85596C (sv) | 1992-05-11 |
| GR860350B (en) | 1986-06-05 |
| GB8602827D0 (en) | 1986-03-12 |
| DK52686A (da) | 1986-08-06 |
| ES551674A0 (es) | 1989-03-16 |
| DK52686D0 (da) | 1986-02-04 |
| JPS61200849A (ja) | 1986-09-05 |
| FI860518A7 (fi) | 1986-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI85596B (fi) | Foerfarande foer framstaellning av en aerosolspray som innehaoller liposomer, daervid anvaend foerpackning och anvaendning av en komposition i foerpackningen. | |
| AT389993B (de) | Herstellung von aerosolzusammensetzungen | |
| AU587472B2 (en) | Liposome inhalation method and system | |
| CA1256798A (en) | System for administration of liposomes to mammals | |
| EP0776202B1 (de) | Liposomal verkapseltes taxol, seine herstellung und seine verwendung | |
| JP6357481B2 (ja) | プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法 | |
| US20090047336A1 (en) | novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation | |
| CA2081474A1 (en) | Direct spray-dried drug/lipid powder composition | |
| PL172328B1 (pl) | Preparat galenowy do miejscowego stosowania i sposób wytwarzania preparatu galenowego do miejscowego stosowania PL PL PL | |
| EP0655237A1 (de) | Medizinische Aerosolformulierung | |
| SA93130496B1 (ar) | ليبوزمات بحويصلات مشكلة heterovesicular liposmes | |
| EP1490026A2 (de) | Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen | |
| WO1987005803A1 (en) | COMPOSITIONS OF LIPOSOMES AND beta2-RECEPTOR ACTIVE SUBSTANCES | |
| KR920008159B1 (ko) | 생리활성 플라보노이드 리포좀의 제조방법 | |
| NO171707B (no) | Fremgangsmaate og forpakning for fremstilling av aerosoler | |
| JPWO2000000178A1 (ja) | リポソーム及び／又はエマルション含有組成物とその作成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: STERWIN A.G. |